Maureen Galmes-Spit
Vice President - Research Laigo Bio
Seminars
Thursday 12th March 2026
Developing Bispecific Antibody Degraders to Achieve Tissue-Specific Degradation of Membrane Proteins
11:00 am
- Engineering bispecific antibody degraders to enable selective, lysosomal degradation of target membrane proteins
- Pairing therapeutic targets with membrane E3 ligases to achieve tissue-specific degradation while sparing healthy tissues
- Expanding therapeutic reach to hard-to-drug and challenging membrane targets
New Data
Tuesday 10th March 2026
Designing Antibody-Based Degraders to Overcome ADC Limitations & Unlock New Therapeutic Opportunities for TPD
8:30 am
As antibody-derived degraders emerge as a powerful alternative to small molecules, this workshop will teach you how to engineer and optimise these biologics to unlock new extracellular degradation strategies.
We will cover:
- Comparing antibody-based degraders with PROTACs and molecular glues to highlight expanded E3 ligase use and tissue-specific targeting enabled by Laigo’s platform
- Leveraging NANOBODY® VHH and antibody engineering to enable precise target engagement and novel extracellular degradation strategies
- Elucidating biodistribution and internalisation pathways to ensure targeted delivery of DACs and minimise off-target effects across tissues and cell types
This workshop is ideal for scientists exploring how antibody-derived scaffolds can extend targeted protein degradation beyond intracellular targets.
